Background
- TNBC, although an aggressive breast cancer (BC) subtype, is highly immunogenic and the only BC subtype where the ICI pembrolizumab is approved.
- However, predictive biomarkers for pembrolizumab benefit are limited.
- The chemokines CXCL9 and CXCL10 attract CD8 T cells into the tumor microenvironment (TME) and are associated with chemotherapy benefit, but little is known about their role in predicting pembrolizumab benefit in TNBC. We investigated the association of CXCL9, CXCL10 and their cognate receptor CXCR3 with TME and ICI efficacy.